ADMS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States...

Stats
Dagens volum	3.15M
Gjennomsnittsvolum	1.34M
Markedsverdi	0.00
EPS	$-0.430 ( 2021-11-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.189 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-24	Mahoney David L	Sell	112 781	Common Stock
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	40 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 2 100 832 \| Sell: 2 425 856

Volum Korrelasjon

Lang: 0.29 (neutral)

Kort: 0.76 (moderate)

Signal:(73.528) Neutral

Adamas Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
BSQR	0.989
SLNO	0.983
BRACU	0.965
XLRN	0.964
LABP	0.962
HCTI	0.961
CEG	0.959
EBAY	0.957
CYT	0.956
CRAI	0.953

10 Mest negative korrelasjoner
AGZD	-0.992
TWKS	-0.967
UNAM	-0.962
HRZN	-0.958
MORF	-0.958
SMSI	-0.954
LPSN	-0.945
BAFN	-0.945
PEBK	-0.941
AHPI	-0.94

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Adamas Pharmaceuticals Korrelasjon - Valuta/Råvare

0.70
( moderate )

-0.08
( neutral )

0.42
( neutral )

0.54
( weak )

-0.70
( moderate negative )

Adamas Pharmaceuticals Økonomi

Annual	2020
Omsetning:	$74.46M
Bruttogevinst:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2020
Omsetning:	$74.46M
Bruttogevinst:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2019
Omsetning:	$54.64M
Bruttogevinst:	$52.17M (95.48 %)
EPS:	$-3.80

FY	2018
Omsetning:	$34.05M
Bruttogevinst:	$33.41M (98.14 %)
EPS:	$-4.87

Financial Reports:

No articles found.

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.